Are you interested in meeting a unique community of life scientists, industries representatives and Neuroinflammation’s experts?
Do you want to learn more about your customers’ current needs and expectations?
Are you eager to gain visibility and show your products?
Don’t miss out on a good opportunity, and have a look at the sponsorship opportunities in our brochure here below.
Download the Sponsorship brochure here!
The 8th edition is supported by:
Gold sponsors
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. They do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. For more information visit novonordisk.com.
Since our founding over 125 years ago, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas by shifting away from a one-size-fits all approach to personalised health care.
They work together across their Pharma and Diagnostics divisions to accelerate research & development and enhance our understanding of disease mechanisms in order to offer a comprehensive portfolio of diagnostic solutions, medicines and digital products that work together to improve healthcare for all.
Silver sponsor
Fujirebio is global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Their group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Their global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to their customers and partners. They value CDMO partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.
Bronze sponsor
Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. The company screened its first target in 2020, selected three development candidates in 2022, advanced its two wholly-owned product candidates into the clinic in 2023, and completed Phase 1 trials for both programs in 2024: VENT-03, a potent, selective, oral cGAS inhibitor, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor. Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor to Novo Nordisk A/S.
Quanterix is a life sciences company that develops and markets an ultra-sensitive digital immunoassay platform. It offers a biomarker detection system, antibodies and ELISA kits, a bead-based immunoassay platform and homebrew assays. Quanterix provides protein biomarker testing, custom assay development services and markets diagnostics technology. Its products find application in detecting central nervous system (CNS), oncology, and cardiac biomarkers at ultra-low levels, measuring inflammatory markers in normal and disease samples, and cytokine levels and profiles in non-critical and critical COVID-19 patients.
MindImmune scientists bring together deep knowledge of both the nervous and immune systems to discover previously unrecognised immune effector mechanisms underlying brain disease. The team is operationalising this knowledge to create its facile drug discovery engine. Their flagship program may herald a breakthrough therapeutic for Alzheimer’s disease.
MindImmune’s therapeutic strategy for Alzheimer’s disease is applicable to a range of neurodegenerative disorders as well as to the other chronic inflammatory conditions.
Monte Rosa Therapeutics is a clinical-stage biotechnology company based in Boston and Basel developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot.